Agios Pharmaceuticals, Inc. (AGIO)
29.88
-0.27
(-0.90%)
USD |
NASDAQ |
Nov 17, 16:00
29.88
0.00 (0.00%)
After-Hours: 20:00
Agios Pharmaceuticals Enterprise Value : 1.199B for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | 1.199B |
| November 13, 2026 | 1.285B |
| November 12, 2026 | 1.295B |
| November 11, 2026 | 1.359B |
| November 10, 2026 | 1.295B |
| November 09, 2026 | 1.272B |
| November 06, 2026 | 1.155B |
| November 05, 2026 | 1.087B |
| November 04, 2026 | 1.272B |
| November 03, 2026 | 1.262B |
| November 02, 2026 | 1.187B |
| October 30, 2026 | 1.223B |
| October 29, 2026 | 1.622B |
| October 28, 2026 | 1.675B |
| October 27, 2026 | 1.670B |
| October 26, 2026 | 1.599B |
| October 23, 2026 | 1.608B |
| October 22, 2026 | 1.620B |
| October 21, 2026 | 1.619B |
| October 20, 2026 | 1.587B |
| October 19, 2026 | 1.483B |
| October 16, 2026 | 1.269B |
| October 15, 2026 | 1.329B |
| October 14, 2026 | 1.248B |
| October 13, 2026 | 1.202B |
| Date | Value |
|---|---|
| October 12, 2026 | 1.239B |
| October 09, 2026 | 1.298B |
| October 08, 2026 | 1.305B |
| October 07, 2026 | 1.297B |
| October 06, 2026 | 1.293B |
| October 05, 2026 | 1.265B |
| October 02, 2026 | 1.298B |
| October 01, 2026 | 1.338B |
| September 30, 2026 | 1.384B |
| September 29, 2026 | 1.398B |
| September 28, 2026 | 1.406B |
| September 25, 2026 | 1.356B |
| September 24, 2026 | 1.375B |
| September 23, 2026 | 1.451B |
| September 22, 2026 | 1.498B |
| September 21, 2026 | 1.437B |
| September 18, 2026 | 1.385B |
| September 17, 2026 | 1.417B |
| September 16, 2026 | 1.378B |
| September 15, 2026 | 1.369B |
| September 14, 2026 | 1.394B |
| September 11, 2026 | 1.416B |
| September 10, 2026 | 1.419B |
| September 09, 2026 | 1.478B |
| September 08, 2026 | 1.413B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Protagonist Therapeutics, Inc. | 7.349B |
| Keros Therapeutics, Inc. | -45.45M |
| ACADIA Pharmaceuticals, Inc. | 2.321B |
| Alnylam Pharmaceuticals, Inc. | 20.79B |
| Anika Therapeutics, Inc. | 154.24M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -65.04M |
| Revenue (Quarterly) | 55.38M |
| Total Expenses (Quarterly) | 120.43M |
| EPS Diluted (Quarterly) | -1.089 |
| Gross Profit Margin (Quarterly) | 92.82% |
| Profit Margin (Quarterly) | -117.4% |
| Earnings Yield | -21.15% |
| Normalized Earnings Yield | -21.15 |